Target price over $300 by the end of 2010. Short-term catalyst is the introduction of the iSlate in early 2010.

Purchased at the secondary price of $3.15/share. This should provide a good floor as the bank tries to return to normalized earnings sometime in 2012.

Healthcare REIT with an incredible yield, considering my purchase price of $6.57. Leases hospitals, and with an increasingly aging population, this should be a continuing need.

Israeli generic drug manufacturer with some name brand products. With many big drugs set to come off patent in the next few years, this should provide a new income stream in the larger half of the business. Obama's healthcare reform should also help push toward generic drugs.

Company makes E911 systems and produces the systems that run text messaging (SMS) on wireless networks. Their SMS support services are growing quickly now, and a strong balance sheet should push this stock up.

AT&T should continue to be a strong dividend stock. Partnership with the iPhone continues to be a growth driver, though they need to work on increasing their network. Should they lose exclusivity with Apple for the iPhone, will rethink this position.